The existing body of literature has been primarily defined with data from tumor, immortal, and primary cells growing in vitro. Collectively, results obtained over decades have been integral to the dogma that up- and down-regulation of proteins can be leveraged as Biomarkers of normal development, homeostasis, and disease. However, in contrast to tissues which are composed of multiple cell types, cell lines growing in culture which theoretically consist of clonal populations. Thus, validation or modification of assay parameters collectively established from decades of cell line data in tissue lysates is key for Biomarker discovery.

IMGENEX offers comprehensive collections of ready-to-use human tissue lysates. These matched tumor and normal adjacent lysates are derived from pathology-defined clinical specimens collected under IRB and HIPAA approved protocols from hospitals around the world. High quality lysates are developed from specimens that have been flash frozen at the collection sites within minutes of removal, maintained in liquid nitrogen, and then processed using protocols optimized for extracting proteins from tissue. Tissue lysates include detailed pathology reports and are useful for a wide range of proteomic studies.

Research Subject Information and Consent Form
Surgical Patient Consent Form

• 1D and 2D gel electrophoresis, protein-protein interactions
• Biomarker screening, antibody characterization
• Breast, lung, colon, stomach, ovary, uterus, cervix, thyroid, kidney, liver
• Tumor/normal adjacent specimens
• Western blot analysis, immunoprecipitation, ELISA
• Wide range of Proteomic applications
• Tumor/Normal Adjacent Tissue Selection

Ready-to-use clinically defined tissue lysates



Tumor tissue specimens are cut and processed using precisely defined protocols to maximize selection of living tumor tissue while avoiding necrotic and normal tissue. Normal adjacent specimens are cut from tissue distal to the tumor, an area grossly free of tumor. All protocols used are IRB & HIPAA approved